All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

TEVA completes $3bn refinancing

TEVA Pharmaceuticals, an Israel-based drug company, signed a new $3bn five year unsecured revolving credit facility on Tuesday that replaces its existing smaller loan.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree